Evolution of Chronic Lesion Tissue in Relapsing-Remitting Patients With Multiple Sclerosis
This study demonstrates that, over a period of up to 5 years, patient-specific enlargement of CLT, when present, progresses at a constant rate and significantly influences brain atrophy and disease progression. In addition, the study underscores CLT as a promising biomarker for RRMS progression and suggests the feasibility of smaller, targeted clinical trials to evaluate treatments aimed at reducing chronic lesion expansion.
Authors
- Samuel Klistorner (ORCID: https://orcid.org/0000-0001-5761-5178)
- Con Yiannikas (ORCID: https://orcid.org/0000-0002-5372-5879)
- Dongang Wang (ORCID: https://orcid.org/0000-0001-5805-0244)
- Michael Harry Barnett (ORCID: https://orcid.org/0000-0002-2156-8864)
- Alexander Klistorner (ORCID: https://orcid.org/0000-0003-0361-6399)
- Chenyu Wang (ORCID: https://orcid.org/0000-0001-7135-7662)
- John DE Parratt
- Andy Shieh
Institutions
- The University of Sydney (AU)
- Royal Prince Alfred Hospital (AU)
- Royal North Shore Hospital (AU)
- Cooperative Trials Group for Neuro-Oncology (AU)
Publication Details
- Journal
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1212/nxi.0000000000200377
- Citations
- 4
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.89